After Drug Store News, or DSN, reported that Arcutis Biotherapeutics announced the Food and Drug Administration has approved the supplemental new drug application, or sNDA, for Zoryve cream 0.15% for the treatment of mild to moderate atopic dermatitis in adults and pediatric patients 6 years of age and older, a spokesperson acting on behalf of Arcutis Biotherapeutics stated that no approval announcement has been made yet.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARQT:
- Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Arcutis Announces New Long-Term Data of Roflumilast Cream 0.15% for the Treatment of Mild to Moderate Atopic Dermatitis (AD) in Adults and Children Down to Age Six Presented at Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference
- Arcutis announces new long-term data from study of roflumilast in AD
- Arcutis Biotherapeutics (NASDAQ:ARQT) Stock Soars on Dermatological Treatments Launch
- Ventyx Biosciences announces appointment of Moore as COO
Questions or Comments about the article? Write to editor@tipranks.com